




# PIVAC-17

## 17<sup>th</sup> International Conference on Progress in Vaccination Against Cancer

27<sup>th</sup>–30<sup>th</sup> September 2017  
«Alexandriou» Conference Hall  
Loutraki, Corinth, Greece

www.pivac17.eu



### Organized by

- The Cancer Immunology and Immunotherapy Center, St. Savas Cancer Hospital
  - The Hellenic Pasteur Institute
- The Hellenic Society of Immuno-Oncology

### Support or Contact

For information please visit <http://pivac17.eu/>  
For further details please mail to [baxevanis@ciic.gr](mailto:baxevanis@ciic.gr)

## Scientific Program



**PIVAC-17**

17<sup>th</sup> International Conference  
on Progress in Vaccination Against Cancer

P r e m i u m   S p o n s o r



The organisers wish to express their appreciation for the significant support provided by sponsors at the 17<sup>th</sup> International Conference on Progress in Vaccination Against Cancer. Their interest and enthusiasm for the meeting has enabled the organizers to provide an impressive scientific programme.



## Meeting Sponsor



The organisers wish to express their appreciation for the significant support provided by sponsors at the 17<sup>th</sup> International Conference on Progress in Vaccination Against Cancer. Their interest and enthusiasm for the meeting has enabled the organizers to provide an impressive scientific programme.



**PIVAC-17**

17<sup>th</sup> International Conference  
on Progress in Vaccination Against Cancer

M e e t i n g   S p o n s o r

**EACR** European Association  
for Cancer Research

The organisers wish to express their appreciation for the significant support provided by sponsors at the 17<sup>th</sup> International Conference on Progress in Vaccination Against Cancer. Their interest and enthusiasm for the meeting has enabled the organizers to provide an impressive scientific programme.



## Meeting Sponsor



The organisers wish to express their appreciation for the significant support provided by sponsors at the 17<sup>th</sup> International Conference on Progress in Vaccination Against Cancer. Their interest and enthusiasm for the meeting has enabled the organizers to provide an impressive scientific programme.



**PIVAC-17**

17<sup>th</sup> International Conference  
on Progress in Vaccination Against Cancer

Meeting Sponsor



The organisers wish to express their appreciation for the significant support provided by sponsors at the 17<sup>th</sup> International Conference on Progress in Vaccination Against Cancer. Their interest and enthusiasm for the meeting has enabled the organizers to provide an impressive scientific programme.



## Meeting Sponsor



The organisers wish to express their appreciation for the significant support provided by sponsors at the 17<sup>th</sup> International Conference on Progress in Vaccination Against Cancer. Their interest and enthusiasm for the meeting has enabled the organizers to provide an impressive scientific programme.



## PIVAC-17

17<sup>th</sup> International Conference  
on Progress in Vaccination Against Cancer

### Scientific Organising Committee

Costas Baxevanis (Chair)

Graham Pawelec

Per Thor Straten

Victor Umansky

Sonia Perez

Menelaos Manoussakis

Marinos Tsiatas





## Day 1 - Wednesday 27 September 2017

13.00 - 20.00 **REGISTRATION** Entrance Lobby of the Alexandrion Conference Hall

13.00 - 14.30 **WELCOME LUNCH**

13.00 - 20.45 **POSTER EXHIBITION**

15.00 - 15.15 **WELCOME BY THE MAJOR OF LOUTRAKI**  
**George Gionis**

### **WELCOME BY THE PIVAC - 17 CHAIR**

**Costas Baxevanis** *Cancer Immunology and Immunotherapy Center,  
St. Savas Hospital, Greece*

### **SESSION 1**

Session Chair: **C. Baxevanis**

15.15 - 15.45 **Rafael Solana** *Maimonides Biomedicine Institute of Cordoba (IMIBIC), Reina Sofia Hospital, University of Cordoba, Spain* "New insights on NK cell-based immunotherapy of cancer"

15.45 - 16.15 **Rolf Kiessling** *Karolinska Institutet, CCK, Stockholm, Sweden* "Combining Adoptive Cell Therapy with DC vaccination for therapy of malignant melanoma"

16.15 - 16.45 **Per thor Straten** *Center for Cancer Immune Therapy, Department of Hematology, University Hospital Herlev, Denmark* "Therapy of solid tumors using T cells and running shoes"

16.45 - 17.15 **COFFEE BREAK**

### **SESSION 2**

Session Chair: **B. Seliger, F. Garrido**

17.15 - 17.45 **Barbara Seliger** *Institute of Medical Immunology, Martin - Luther - University Halle - Wittenberg, Halle, Germany* "Tumor-induced immune escape mechanisms due to deregulation of immune relevant components"

17.45 - 18.15 **Federico Garrido** *Departamento de Bioquímica, Biología Molecular III e Inmunología, Facultad de Medicina, Universidad de Granada, Spain* "Cancer Immune Escape: HLA Class I Loss And Tumour Tissue Architecture"

18.15 - 20.00 **Proffered Papers**

**Toos Daemen** *Department of Medical Microbiology, Tumor Virology and Cancer Immunotherapy, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands* "Semliki Forest Virus-based anticancer vaccines"



## PIVAC-17

17<sup>th</sup> International Conference  
on Progress in Vaccination Against Cancer

**D.H. Madsen** *Center for Cancer Immune Therapy (CCIT), Copenhagen University Hospital, Herlev, Denmark* “**Tumor extracellular Matrix as a potent regulator of intratumoral immunity**”

**Ch. Delle, D.H. Madsen** *Center for Cancer Immune Therapy (CCIT), Dept. of Haematology, Herlev Hospital, Herlev Ringvej, Denmark* “**Is the activity of tumor-infiltrating T cells modulated by colon cancer cells?**”

**M. Eckey** *JPT Peptide Technologies GmbH, Berlin, Germany* “**TERS-routine application of a new tool for standardizing functional T-cell assays**”

**Elena Quaglino** *Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy* “**TENM4 emerges as a potential target for Triple Negative Breast Cancer Stem Cells immune-targeting**”

**Barbara-ann Guinn** *School of Life Sciences - Biomedical Science, University of Hull, Hull, UK* “**New targets for the immunotherapy of adult B-acute lymphocytic leukaemia**”

**Barbara-ann Guinn** *School of Life Sciences - Biomedical Science, University of Hull, Hull, UK* “**Can a cancer-testis antigen act as biomarker for early stage ovarian cancer?**”

20.00 - 22.00 **WELCOME RECEPTION**



## Day 2 - Thursday 28 September 2017

### SESSION 3

Session Chair: **W.H. Fridman**

- 09.00 - 09.30 **Efstathios Stratikos**, *National Center for Scientific Research Demokritos, Agia Paraskevi, Athens, Greece* “Modulating intracellular antigen processing for enhancing tumour antigenicity”
- 09.30 - 10.00 **Wolf Herve Fridman**, *INSERM Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France* “Cancer microenvironments: prognostic and theranostic impacts”
- 10.00 - 10.30 **Doriana Fruci**, *Immuno-Oncology Laboratory, Ospedale Pediatrico Bambino, Rome, Italy* “Clinical relevance of tumor-infiltrating immune cells in neuroblastoma”
- 10.30 - 11.00 **Ioannis Pateras**, *Department of Histology and Embryology, University of Athens, Greece* “Biomarkers in Inflammation- relevance to cancer”

11.00 - 11.30 **COFFEE BREAK**

### SESSION 4

Session Chair: **C. Figdor**

- 11.30 - 12.00 **Gustav Gaudernack**, *Department of Immunology, Institute for Cancer Research, University Hospital-Radiumhospitalet, Oslo, Norway* “Clinical trials with a second generation hTERT vaccine, UV1. Single agent therapy and combination with checkpoint inhibitors”
- 12.00 - 12.30 **Sjoerd van der Burg**, *Leiden University Medical Center, The Netherlands* “Cancer Immunotherapy, not without vaccination”
- 12.30 - 13.00 **Carl Figdor**, *Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands* “21<sup>st</sup> Century Cancer Vaccines”

13.00 - 13.30 **COFFEE BREAK**

### SESSION 5

Session Chair: **P. Coulie**

- 13.30 - 14.00 **Federica Cavallo**, *Molecular Biotechnology Center, University Turin, Italy* “The cystine/ glutamate antiporter xCT: A new cancer stem cell target for anticancer vaccines”
- 14.00 - 14.30 **Pierre Coulie**, *de Duve Institute, Université Catholique de Louvain, Brussels, Belgium* “Immunogenicity of primary breast carcinomas”
- 14.30 - 15.00 **Kostas Kosmatopoulos**, *Vaxon Biotech, Paris, France* “Optimized cryptic peptides: a universal neoantigen therapeutic cancer approach”



## PIVAC-17

17<sup>th</sup> International Conference  
on Progress in Vaccination Against Cancer

15.00 - 16.30 **LUNCH**

Chairs: **F. Cavallo, C. Baxevanis**

16.30 - 18.15 **Proffered Papers**

**Simon Klaessens**, *Ludwig Institute for Cancer Research, Brussels; Belgium. de Duve Institute, Université catholique de Louvain, Brussels, Belgium* “**Tryptophan 2,3-dioxygenase, an enzyme involved in tumour immune escape, is positively regulated by its substrate tryptophan**”

**Alvaro Lladser**, *Laboratory of Gene Immunotherapy, Fundacion Ciencia @ Vida, Santiago, Chile* “**Vaccination-induced skin-resident and circulating memory CD8+ T cells collaborate to mediate broad protection against cutaneous melanoma**”

**Marit R. Myhre**, *Department of Cellular Therapy, Section for Cancer Immunology, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway* “**Exploiting CD4+ T cells for adoptive cell therapy in cancer**”

**Thomas W. Smith**, *Department of Surgery, Loyola University Medical Center; Department of Surgery, Medical University of South Carolina, USA* “**Genetically enhanced T cells with IL2R $\alpha$  lead to increased survival and proliferation**”

**Marius Strioga**, *National Cancer Institute, Vilnius, Lithuania* “**Chemoimmunotherapy using autologous dendritic cell vaccines for the treatment of recurrent glioblastoma multiforme**”

**Raquel Tarazona**, *Immunology Unit, University of Extremadura, Cáceres, Spain* “**Increased expression of activating receptors and recovery of NK cell function in Acute Myeloid Leukaemia patients after in vitro culture with IL-15**”

**Claudia Wurzenberger**, *Immunocore Ltd., Milton Park, Abingdon, Oxfordshire, UK* “**ImmTACTM: From TCR discovery to bi-specific immunotherapeutic agents for the treatment of cancer**”

18.15 -18.45 **COFFEE BREAK**

“Satellite Session by the industry”

18.45 - 19.15 **Paul Lehmann**, *Case Western Reserve University, USA* “**Tumor antigen recognition by healthy individuals and cancer patients**”

19.15 - 19.45 **Robert Stad**, *Perkin Elmer, “Immunophenotyping the Tumor Microenvironment in FFPE Sections”*

20.00 - 22.00 **DINNER**



## Day 3 - Friday 29 September 2017

### SESSION 6

Session Chair: **V. Umansky**

- 09.00 - 09.30 **Victor Umansky**, *Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany* "Accumulation of myeloid-derived suppressor cells in melanoma microenvironment and their targeting"
- 09.30 - 10.00 **Vincenzo Bronte**, *Department of Medicine, University Hospital, University of Verona, Italy* "Myeloid cells assist tumor progression by molecular mechanisms either dependent or independent from adaptive immunity"
- 10.00 - 10.30 **Suzanne Ostrand-Rosenberg**, *Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD* "The good, the bad, and the in-between: immune suppression, obesity, and tumor progression"

### 10.30 - 11.00 COFFEE BREAK

### SESSION 7

Session Chair: **S. Ostrand-Rosenberg**

- 11.00 - 11.30 **Vincenzo Cerundolo**, *MRC Human Immunology Unit, University of Oxford, UK* "Amino acid degrading enzymes and their role in tumour immune escape mechanisms"
- 11.30 - 12.00 **Benoit van den Eynde**, *Ludwig Institute for Cancer Research, Oxford, UK* "Mechanisms of resistance to cancer immunotherapy"

### 12.00 - 12.15 POSTER AWARDS

### 12.15 - 14.00 LUNCH

### SESSION 8

Session Chair: **G. Pawelec**

- 14.00 - 14.30 **Gunter Hammerling** *Division of Molecular Immunology, German Cancer Research Center Heidelberg, Germany* "Reprogramming of the tumor microenvironment for efficient cancer immunotherapy"
- 14.30 - 15.00 **Graham Pawelec** *Second Department of Internal Medicine, University of Tübingen, Germany* "Immunotherapy of Cancer: triumphs and challenges, and the impact of immunosenescence"
- 15.00 - 15.30 **Cornelis Melief** *Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, The Netherlands* "Combination immunotherapy against cancers expressing viral or neo-antigens"



## PIVAC-17

17<sup>th</sup> International Conference  
on Progress in Vaccination Against Cancer

15.30 - 16.00 COFFEE BREAK

### SESSION 9

Session Chair: **C. Gouttefangeas**

16.00 - 16.30 **Gosse Adema** *Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands* “Immuno-combination therapies for cancer”

16.30 - 17.00 **Antonia Dimitrakopoulou-Strauss** *Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany* “Therapy monitoring of immune checkpoint inhibitors in patients with metastatic melanoma with PET-CT”

17.00 - 17.30 **Cecile Gouttefangeas** *Group leader at the Institute for Cell Biology, Department of Immunology, Tübingen, Germany* “Immunomonitoring as a tool to identify biomarkers predicting the outcome of immunotherapy-treated patients”

17.30 - 19.00 Cancer Immunology and Immunotherapy editorial board meeting

19.00 - 20.30 DINNER

## Saturday 30, September 2017

Free day - Excursion to Epidaurus old theater, Ancient Mycenae, Nafplion

